StockTipsArenaBeta

BUY Biocon Ltd — Vikas Sethi, Sethi Finmart

BUYBiocon Ltd
Biocon share price target & all analyst calls

byVikas Sethi, Sethi FinmartHorizon: 1–3 months19 Oct 2026via Zee Business (Live)

Entry₹344.15Inferred
Target₹450
Total upside +30.76%
Stop lossNot given
CMP₹340Just now
Active-1.21%+32.35%upside left 3 mo left
Follow Vikas Sethi for new calls(39% target hit, 127 closed calls)Get alertsWatch BIOCON for new buy/sell callsGet alertsSee 2 other Short-term calls on BIOCONSee 20 other Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 20 Oct, 2:36 pm IST
7 supporting3 opposing
Supports the BUY call (7)

RSI at 16 — oversold territory

Technicals · rsi·20 Oct · today

Biocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch dates

NewsCnbc-Tv18·14 Oct · 6d ago

(opens in new tab)

Biocon Malaysia arm gets UK regulator approval for Semglee fill finish unit

NewsCnbc-Tv18·25 Sept · 4w ago

(opens in new tab)

Biocon's subsidiary received a positive opinion from EMA's CHMP for its Pertuzumab biosimilar (Pebrilzo) for HER2-positive breast cancer treatment. This is the first biosimilar to receive such recomme

BSE · Company Update·21 Sept · 4w ago

(opens in new tab)

Biocon's biosimilar Pertuzumab has received a positive recommendation from the EMA's CHMP under a new tailored clinical approach, marking a significant regulatory milestone.

NSE · Press Release·21 Sept · 4w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (3)

MACD below its signal line — bearish momentum

Technicals · macd·20 Oct · today

1 other SEBI-registered advisor has an active short-term SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·9 Oct · 1w ago

2 advisors have active long-term SELL calls on this stock

Advisor consensus · adjacent horizon·15 Jul · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Vikas Sethi, Sethi Finmart

Every call and its outcome